Item 2.01 Completion of Acquisition or Disposition of Assets

On November 7, 2022, Innovation1 Biotech Inc., a Nevada corporation (the "Company"), completed the disposition (the "Disposition") of all of the assets, including intellectual property assets, relating to Mioxal®, a nutraceutical complex composed of essential amino acids, natural coenzymes and minerals, to Ingenius Biotech S.L., a corporation organized under the laws of Spain ("Ingenius"). The Disposition was completed pursuant to the terms of that certain Agreements Relating to the Transfer of the Mioxal Product, dated as of November 7, 2022, by and between the Company and Ingenius (the "Disposition Agreement").

As part of the Disposition, pursuant to the Disposition Agreement, certain shareholders of the Company transferred an aggregate of 350,000 shares of the Company's currently outstanding common stock, par value $0.001 per share, to Ingenius and Ingenius agreed to pay the Company (i) $100,000 upon the first to occur of Ingenius' first sale or commercialization of the Mioxal Product or Ingenius' sale, license, transfer or other disposition of the Mioxal Product to a third party, and (ii) a 5% royalty on worldwide net sales of the Mioxal Product by Ingenius or a third party commencing on the date of the first sale of Mioxal Products and ending on the 18-month anniversary of the last to expire of any patent covering the Mioxal Products. Additionally, Ingenius agreed to release the Company from all of its liabilities and obligations relating to the Mioxal Products and indemnify the Company from all claims relating to the Mioxal Product following the date of the Disposition.

The foregoing description of the Disposition Agreement is qualified in its entirety by reference to the Disposition Agreement filed as Exhibit 10.1 to this Current Report.

Item 7.01. Regulation FD Disclosure

On November 14, 2022, the Company posted an updated presentation (the "Presentation") which is available in the Presentations section of the Company's website at https://www.innovation1bio.com/company-information/presentations. A copy of the Presentation is included as Exhibit 99.1 to this Current Report.

The Company intends to use the Presentation in presentations to investors and analysts from time to time in the future. The furnishing of the information in this Current Report is not intended to, and does not, constitute a determination by the Company that the information in this Current Report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company. The information in the materials is presented as of November 11, 2022, and the Company does not assume any obligation to update such information in the future.

The information in Item 7.01 of this Current Report shall not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



              Agreements Relating to the Transfer of the Mioxal Product, dated as
  10.1      of November 7, 2022, by and between Innovation1 Biotech Inc. and
            Ingenius Biotech S.L.

  99.1        Innovation1 Biotech Inc. Presentation dated November 14, 2022.

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            Document)





2

© Edgar Online, source Glimpses